Bio-Techne - TECH Stock Forecast, Price & News

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Bio-Techne in the last twelve months. There are currently 1 sell rating and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" TECH shares.
View TECH analyst ratings or view top-rated stocks.

5 Wall Street analysts have issued twelve-month target prices for Bio-Techne's shares. Their TECH share price forecasts range from $360.00 to $575.00. On average, they expect the company's share price to reach $475.00 in the next year. This suggests a possible upside of 68.1% from the stock's current price.
View analysts price targets for TECH or view top-rated stocks among Wall Street analysts.

Bio-Techne's stock was trading at $517.34 on January 1st, 2022. Since then, TECH shares have decreased by 45.4% and is now trading at $282.54.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 1st 2022.
View our TECH earnings forecast.

Bio-Techne Co. (NASDAQ:TECH) announced its quarterly earnings data on Thursday, August, 4th. The biotechnology company reported $2.05 EPS for the quarter, missing analysts' consensus estimates of $2.08 by $0.03. The biotechnology company had revenue of $288.30 million for the quarter, compared to the consensus estimate of $287.04 million. Bio-Techne had a trailing twelve-month return on equity of 16.97% and a net margin of 24.61%. The business's quarterly revenue was up 11.3% on a year-over-year basis. During the same period last year, the company earned $1.67 EPS.

Bio-Techne announced a quarterly dividend on Friday, August 5th. Investors of record on Monday, August 15th will be given a dividend of $0.32 per share on Monday, August 29th. This represents a $1.28 dividend on an annualized basis and a dividend yield of 0.45%. The ex-dividend date is Friday, August 12th.
Read our dividend analysis for TECH.

Bio-Techne (NASDAQ:TECH) pays an annual dividend of $1.28 per share and currently has a dividend yield of 0.44%. The dividend payout ratio is 19.34%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, TECH will have a dividend payout ratio of 13.26% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for TECH.

95 employees have rated Bio-Techne Chief Executive Officer Charles Kummeth on Glassdoor.com. Charles Kummeth has an approval rating of 73% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Bio-Techne investors own include Paychex (PAYX), Gilead Sciences (gild), NVIDIA (NVDA), AbbVie (ABBV), Amgen (AMGN), Abbott Laboratories (ABT), Cisco Systems (CSCO), Johnson & Johnson (JNJ), AT&T (T) and Boeing (BA).

Bio-Techne trades on the NASDAQ under the ticker symbol "TECH."

Bio-Techne's stock is owned by a variety of institutional and retail investors. Top institutional investors include State Street Corp (4.00%), DF Dent & Co. Inc. (1.74%), Champlain Investment Partners LLC (1.26%), Allspring Global Investments Holdings LLC (1.22%), Massachusetts Financial Services Co. MA (1.21%) and Northern Trust Corp (1.05%). Insiders that own company stock include Alpna Seth, Brenda S Furlow, Brenda S Furlow, Charles R Kummeth, Charles R Kummeth, Glenn Hedde, Harold J Wiens, James Hippel, John L Higgins, Kim Kelderman, Norman David Eansor, Robert V Baumgartner and Roeland Nusse.
View institutional ownership trends.

Shares of TECH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of TECH stock can currently be purchased for approximately $282.54.

Bio-Techne (NASDAQ:TECH) has a market capitalization of $11.08 billion and generates $1.11 billion in revenue each year. The biotechnology company earns $272.05 million in net income (profit) each year or $6.62 on an earnings per share basis.

The company employs 3,000 workers across the globe.

Bio-Techne's mailing address is 614 MCKINLEY PLACE NE, MINNEAPOLIS MN, 55413. The official website for the company is www.bio-techne.com. The biotechnology company can be reached via phone at (612) 379-8854, via email at ir@bio-techne.com, or via fax at 612-656-4400.